Skip to main content

Fiscal Wizard · Single-issue tearsheet

IQV / Aug 13, 2026 Run #13796

IQV

IQVIA Holdings Inc.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Composite verdict

D 38.6 / 100
Gated stand-aside 0 drivers · 5 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 9th of 11 in Diagnostics & Research

rescore-sweep
Technical synthesisRegime: volatile uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -76%
Asset value $39.51Earnings power value $51.64Price $241.71

Priced above its no-growth earnings power value ($51.64/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

38.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Forward P/E 84
PEG 0
Greenblatt EY 76
Margin of Safety 0
EV/EBITDA 75
OCF to Net Income 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 44 signals shown.

Risk Gates

5 blocking 9 caution

5 guards active, 44 signals gated.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for IQV.